Brokerages Set Catalent, Inc. (NYSE:CTLT) Target Price at $59.83

Shares of Catalent, Inc. (NYSE:CTLT) have earned an average recommendation of “Hold” from the eight ratings firms that are covering the firm, MarketBeat Ratings reports. Eight research analysts have rated the stock with a hold recommendation. The average twelve-month price target among brokers that have issued ratings on the stock in the last year is $59.83.

Several equities research analysts have recently weighed in on the company. Barclays increased their price target on Catalent from $47.00 to $63.00 and gave the company an “equal weight” rating in a research note on Friday, June 28th. StockNews.com initiated coverage on shares of Catalent in a report on Saturday. They set a “hold” rating for the company. Baird R W lowered shares of Catalent from a “strong-buy” rating to a “hold” rating in a research note on Tuesday, September 24th. Robert W. Baird reissued a “neutral” rating and set a $63.50 target price on shares of Catalent in a research note on Tuesday, September 24th. Finally, William Blair restated a “market perform” rating on shares of Catalent in a report on Tuesday, September 3rd.

Catalent Trading Up 0.0 %

CTLT opened at $60.66 on Friday. The company has a debt-to-equity ratio of 1.35, a current ratio of 2.52 and a quick ratio of 1.96. Catalent has a fifty-two week low of $31.80 and a fifty-two week high of $61.20. The company’s 50 day moving average price is $60.06 and its two-hundred day moving average price is $57.68. The firm has a market capitalization of $10.98 billion, a price-to-earnings ratio of -9.93, a PEG ratio of 2.14 and a beta of 1.15.

Catalent (NYSE:CTLT) last issued its quarterly earnings data on Thursday, August 29th. The company reported $0.57 earnings per share for the quarter, topping the consensus estimate of $0.44 by $0.13. The company had revenue of $1.30 billion for the quarter, compared to analysts’ expectations of $1.23 billion. Catalent had a negative net margin of 22.72% and a negative return on equity of 0.56%. As a group, research analysts predict that Catalent will post 0.95 earnings per share for the current year.

Insiders Place Their Bets

In other news, SVP Scott Gunther sold 666 shares of the company’s stock in a transaction dated Friday, August 2nd. The shares were sold at an average price of $59.55, for a total transaction of $39,660.30. Following the transaction, the senior vice president now owns 39,635 shares in the company, valued at approximately $2,360,264.25. This represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. In other Catalent news, SVP Scott Gunther sold 666 shares of the firm’s stock in a transaction that occurred on Friday, August 2nd. The stock was sold at an average price of $59.55, for a total value of $39,660.30. Following the completion of the sale, the senior vice president now owns 39,635 shares of the company’s stock, valued at approximately $2,360,264.25. This trade represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, insider David Mcerlane sold 1,994 shares of the business’s stock in a transaction that occurred on Thursday, September 26th. The shares were sold at an average price of $59.97, for a total value of $119,580.18. Following the sale, the insider now owns 36,304 shares of the company’s stock, valued at approximately $2,177,150.88. This represents a 0.00 % decrease in their position. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 12,410 shares of company stock worth $732,680. 0.31% of the stock is currently owned by company insiders.

Institutional Investors Weigh In On Catalent

Institutional investors and hedge funds have recently made changes to their positions in the business. V Square Quantitative Management LLC boosted its position in shares of Catalent by 34.0% during the fourth quarter. V Square Quantitative Management LLC now owns 5,332 shares of the company’s stock valued at $240,000 after buying an additional 1,352 shares during the last quarter. Virtu Financial LLC purchased a new stake in Catalent in the 4th quarter valued at $432,000. Royal London Asset Management Ltd. lifted its stake in Catalent by 5.0% during the 4th quarter. Royal London Asset Management Ltd. now owns 63,727 shares of the company’s stock valued at $2,863,000 after acquiring an additional 3,041 shares in the last quarter. Mather Group LLC. purchased a new position in Catalent during the 1st quarter worth $52,000. Finally, Clearview Wealth Advisors LLC bought a new stake in shares of Catalent in the 1st quarter worth $356,000.

Catalent Company Profile

Catalent, Inc, together with its subsidiaries, develops and manufactures solutions for drugs, protein-based biologics, cell and gene therapies, and consumer health products worldwide. It operates in two segments, Biologics, and Pharma and Consumer Health. The Biologics segment provides formulation, development, and manufacturing for biologic proteins, cell gene, and other nucleic acid therapies; pDNA, iPSCs, oncolytic viruses, and vaccines; formulation, development, and manufacturing for parenteral dose forms, including vials, prefilled syringes, and cartridges; and analytical development and testing services for large molecules.